Use of animal models to develop antiaddiction medications.
about
Glutamatergic targets for enhancing extinction learning in drug addictionNucleus accumbens dopamine/glutamate interaction switches modes to generate desire versus dread: D(1) alone for appetitive eating but D(1) and D(2) together for fearAddiction and brain reward and antireward pathways.The selective D₃ receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preferencePreclinical evidence of new opioid modulators for the treatment of addiction.Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment.
P2860
Use of animal models to develop antiaddiction medications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of animal models to develop antiaddiction medications.
@en
Use of animal models to develop antiaddiction medications.
@nl
type
label
Use of animal models to develop antiaddiction medications.
@en
Use of animal models to develop antiaddiction medications.
@nl
prefLabel
Use of animal models to develop antiaddiction medications.
@en
Use of animal models to develop antiaddiction medications.
@nl
P2860
P1476
Use of animal models to develop antiaddiction medications.
@en
P2093
Eliot L Gardner
P2860
P2888
P304
P356
10.1007/S11920-008-0061-Y
P407
P577
2008-10-01T00:00:00Z